Phase II study of durvalumab anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

Johnson, B; Haymaker, CL; Parra, ER; Soto, LMS; Wang, XM; Thomas, JV; Dasari, A; Morris, V; Raghav, K; Vilar, E; Kee, BK; Eng, C; Parseghian, CM; Wolff, RA; Lee, Y; Lorenzini, D; Laberiano-Fernandez, C; Verma, A; Lang, WH; Wistuba, II; Futreal, A; Kopetz, S; Overman, MJ

Johnson, B (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022; 10 (8):

Abstract

Background Monotherapy with immune checkpoint blockade is ineffective for patients (pts) with microsatellite stable (MSS) metastatic colorectal cancer......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索